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Abstract
“Mutualism” is a well-defined relationship that describes a form of cooperation between 
two living organisms of different species that ends up with a beneficial outcome for each 
one. Any disruption to such a relationship by an external trigger or a potential intruder 
puts at risk the well-being of both. In humans, oral and gut microbiota provide a note-
worthy model of beneficial mutualism. Multiple recent evidences point to the possible 
pathologic consequences of a disruption to this ecosystem (altered microbiota profile 
or dysbiosis) on human well-being. The gut-joint axis found its clear way “Proof of 
Principle” in the pathogenesis of autoimmune rheumatic diseases including rheuma-
toid arthritis (RA), seronegative spondyloarthropathies, and Behcet’s disease in a num-
ber of studies. Current therapeutic trends are directed towards the diverse biologic and 
immune-pathogenic factors involved in the disease process. Addressing dysbiosis in RA 
features an attractive future therapeutic target.  In this chapter, authors aim to explore the 
recent evidences regarding the pathogenic role of “gut dysbiosis” in rheumatoid arthritis 
(RA), highlighting the spectrum of immune-pathogenic events that might contribute to 
disease evolution and inspecting future directives of research.
Keywords: Mutualism, microbiota, dysbiosis, pathogenesis, autoimmune rheumatic 
diseases, rheumatoid arthritis
1. Rheumatoid Arthritis and The Microbiome Theory “The Revival of  
an Old Hypothesis”
Rheumatoid arthritis (RA) is a systemic immune-mediated chronic inflammatory disease that 
predominantly targets diarthrodial joints contributing to synovial inflammation, joint destruc-
tion, and deformity. The disease has been initially recognized as a complex  genetically based 
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inflammatory joint disease, a concept that was redefined toward a multifactorial immune-
mediated etiology. The etiopathogenesis of rheumatoid arthritis is typically a challenge 
incorporating complex network of genetic factors (HLA genes), environmental and biologi-
cal factors (infections, a dominant pro-inflammatory profile, dysbiosis), as well as individual 
habits (smoking) interacting to shape up disease phenotype [1, 2].
An infectious etiology of RA has been proposed for decades, Banntyne and Wohlmann in 
1896 were the first to suggest a mycobacterial etiology behind the development of rheuma-
toid arthritis, a theory that awaited solid scientific evidence. The hypothesis of “molecular 
mimicry” and cross-reactivity between epitopes of microbial origin with a self-protein was 
among the proposed mechanisms to explain the role of infectious agents in the breakdown of 
immune tolerance in RA. Certain viral infections like Epstein-Barr virus (EBV), cytomegalo-
virus (CMV), and Parvovirus B19 have been additionally claimed as potential etiopathogenic 
agents in RA [3–9].
1.1. The oral sepsis hypothesis
In the 1900s, the oral sepsis hypothesis and its relation to arthritis led to the use of teeth 
extraction as a prevalent treatment of disease for several decades. The impact of polymicro-
bial phylotypes and the pro-inflammatory burden in periodontitis proved its contribution to 
the pro-inflammatory drive in RA. The Porphyromonas gingivalis, a Gram-negative anaerobe 
bacterium and part of periodontopathic microbiome, contributes to protein citrullination, 
which leads to anticitrullinated autoantibody (ACPA) formation and joint inflammation in 
RA [6–13].
The infectious profile further extended to include other pathogenic bacterial species as 
wells as cell membrane proteins of mycoplasma in RA like Proteus mirabilis (sharing sequence 
similarities to peptide sequences at amino acid position 67–74 of the HLA-shared epitope in RA 
and bacterial-specific antibodies detected in sera of RA patients) [14, 15]. The presence of spe-
cific Escherichia coli, Mycoplasma fermentans, and Klebsiella pneumonia in the gut has been 
associated with RF positivity and has been linked to inflammatory arthritis in many ethnic 
populations [16].
1.2. The infectious hypothesis and therapeutic evidences
The relationship between infections and arthritis was indirectly reinforced by the time anti-
microbials showed an observable beneficial effect in the amelioration of arthritis. In the 1940s, 
sulfasalazine was the first rationally designed drug in the field of rheumatology, where RA 
was thought to be caused by Streptococci found in milk. Sulfasalazine was designed as a 
deliberate attempt to combine a sulfonamide antibiotic with a salicylate anti-inflammatory 
agent through an azo bond. Such “combination therapy” brought up good initial responses 
in RA as well as enteropathies. The triple DMARD therapy (a combination of methotrexate, 
sulfasalazine and hydroxychloroquine) currently stands among the first few recommenda-
tions in RA patients with poor prognostic features and moderate to high levels of disease 
activity [17–21].
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Certain antibiotics like tetracycline have proven efficacy in the treatment of early seropositive 
RA which led to the approval of minocycline, as a DMARD [22, 23]. Clarithromycin is another 
example that gave observable beneficial effects in some refractory cases [24]. Treatment with 
probiotics, particularly Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii, showed 
protective effects in NSAID-treated animal models of arthritis. Theories regarding supple-
mentations of microbiome-derived molecules with immune-modulating properties (e.g., 
Polysaccharide A, short-chain fatty acids) provide promising novel immune regulatory 
effects by possibly downregulating pro-inflammatory cytokines with upregulation of the 
anti-inflammatory profile [25–27].
2. The human gut ecosystem
Mutualism is a well-defined relationship between living organisms. The term describes a 
form of cooperation between two living organisms of different species that ends up with 
a beneficial outcome for each one. Partners in a mutualistic relationship make headway 
together with each forming a part of the other’s environment and maintaining its homeo-
stasis in a typically harmless yet useful way. A disruption to such a relationship by an 
external trigger or a potential intruder puts at risk the well-being of both. In humans, oral 
and gut microbiota provide a noteworthy model of beneficial mutualism. Multiple recent 
evidences point to the possible pathologic consequences of a disruption to this ecosystem 
(altered microbiota profile or dysbiosis) on human well-being. The gut-joint axis found 
its clear way “Proof of Principle” in the pathogenesis of autoimmune rheumatic diseases 
including RA, seronegative spondyloarthropathies, and Behcet’s disease in a number of 
studies.
The term “microbiota” is defined as the ecological community of symbiotic, commensal, and 
pathogenic microorganisms that literally inhabit the human body and effectively contribute 
to human health and might contribute to disease. According to their contributions to human 
health, they can be classified to symbiomes and pathobiomes. The symbiome microbiota are 
groups of microorganisms predominantly bacterial as well as fungal (previously recognized 
as normal flora) that get acquired at birth and inhabit every part of the human body from the 
skin to mucosa (mouth, eyes, gut, and genital tracts). The alimentary tract represents an estab-
lished microbial habitat for almost 29–30% of the overall commensal/symbiome population in 
the human body. They involve over 500 bacterial species encoding around three million dif-
ferent genes constituting a complex challenging ecosystem, difficult to differentially analyze 
or understand [28, 29].
2.1. The development of the human microbiota profile
The general composition of gut microbiota is much similar in most healthy individuals; how-
ever, the individuals’ microbiota profile retains a highly personalized pattern (fingerprint). 
This pattern helps to keep in situ homeostasis in healthy individuals; therefore triggers of 
dysbiosis are expected to offer a threat to the humans’ well-being in a variety of forms.
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At birth: The initial shape up of the different microbial colonies of the gut begins as early as child-
birth by the time the newborn gets exposed to microorganisms that inhabit the maternal genital 
tract during normal vaginal delivery (first encounter), maternal fecal bacteria, or the skin in the 
case of caesarian section. The fetal fingerprint of microbiota gets additionally shaped up by the 
skin as well as breast milk microbiota that add their signature to this microbial network [30].
Adulthood: The typical adult microbiota profile emerges by the end of the first year with more 
than 1000 different species from a dozen different divisions colonizing the gastrointestinal tract 
(4 × 1013 colonizing bacteria). The profile becomes increasingly stable with age. The acquired 
bacterial species pass through a series of modifications with colonies competing for survival, 
alternating their dominance aiming to establish phylogenetic richness and species diversity at 
the same time. Serial microbial evolutions are proven to be largely dependent on a multiplicity 
of host as well as environmental factors (the host genetics, the maternal microbiota, and mode 
of delivery as major determinants). Breast milk composition is another proven shaping factor 
of individuals’ microbiota profile (Bifidobacterium is among the dominant gut microbiota in 
breast-fed infants compared to artificially fed ones and is deficient in patients with RA). Aging; 
lifestyle patterns including diet, smoking, and obesity; and infections also contribute [31–34].
2.2. The identification and characterization of gut microbiota
The human microbiome project served as a major contributor toward better understanding of the 
human microbiome. For a sufficient period of time, the conventional culture-based methods were 
the only methods available and routinely used for identification of gut microbiota, with over 500 
bacterial species successfully isolated, cultured, and characterized from the human GI tract [35].
The majority of gut microbiota (over 80%) could not be technically cultivated ranking the cul-
ture-based methods as an investigative technique of limited value in determining the actual 
microbial diversity. The revolutionary era of the human microbiome project announced in 
2007 and the utilization of novel culture-independent molecular techniques have success-
fully contributed to the in-depth understanding of such complex human microbiome net-
work. Such culture-independent techniques target the highly conserved 16S ribosomal RNA 
(rRNA) gene sequence (a component the 30S subunit of prokaryotic ribosomes) of bacterial 
and archaeal microorganisms. Universal PCR primers targeting these conserved regions 
can be used for gene amplification to provide the complete nucleotide sequence of the 16S 
rRNA without prior knowledge of which bacterial species are present. Concomitantly, the 
16S rRNA gene also contains hypervariable regions that provide species-specific signature 
sequences and enable unbiased bacterial identification utilizing next-generation sequencing 
platforms. Examples of these molecular techniques include quantitative polymerase chain 
reaction (qPCR), temperature or denaturing gradient gel electrophoresis (TGGE or DGGE), 
terminal-restriction fragment length polymorphism (T-RFLP), and fluorescent in situ hybrid-
ization (FISH). The next-generation sequencing and phylogenetic microarrays promote the 
in-depth analysis of the complete phylogenetic diversity of the intestinal microbiota, whereas 
the whole-genome shotgun sequencing is a technique currently applied for identification of 
the metabolic and enzymatic pathways present in these microbial communities. Such tech-
niques were able to identify a portion of predominant species in the human gut [36–38].
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Genomic culture-independent techniques disclosed that the human intestine is dominated 
by two divisions of bacteria, Bacteroidetes and Firmicutes, and both contribute to more than 
two-thirds of the total gut microbiota including anaerobes such as Bacteroides, Porphyromonas, 
Bifidobacterium, Lactobacillus, and Clostridium [13, 34, 39, 40].
2.3. The human-microbiota interdependence
Microbiota are involved in a number of structural, biological, protective, and metabolic pro-
cesses including angiogenesis, postnatal intestinal maturation, and xenobiotic metabolism. They 
are additionally involved in the synthesis of vitamins, the digestion, and uptake of nutrients. 
Microbiota are capable of metabolically simplifying nutritional components through the pro-
cess of fermentation; an important example is the indigestible carbohydrates (complex starch 
and dietary fibers) as well as short-chain fatty acids (SCFA, e.g., acetate, butyrate, and propio-
nate) which constitute a critical prerequisite in a number of host physiological functions [41].
2.3.1. Microbiota and immunity
A unique harmonious and complex interplay exists between gut microbiota and the local as well 
as the systemic immune response in humans. Colonizing microbiota and their products have a 
profound effect on the development and maintenance of the immune system integrity [42–45].
2.3.1.1. The microbiota and T-cell differentiation, proliferation, and functions
Evidences support the existence of immune cross talks between the microbiota-derived prod-
ucts and the gut epithelium that involves molecular exchange of bacterial signals recognized 
by host receptors to mediate beneficial outcomes for both the microbiome and human beings 
[42–47]. The gut microbiota have the potential to effectively stimulate and direct the host 
innate and adaptive immune responses in humans by triggering instructional signals to the 
immune cells, particularly regulatory T (Treg)-cell and T-helper (Th) cell differentiation.
2.3.1.2. Short-chain fatty acids and Treg cells
SCFAs are actively produced by anaerobic microbiota in the colon as fermentation products 
of digestion-resistant dietary fibers [46, 47]. SCFAs produced locally in the colon are either 
absorbed and metabolized within the colonocytes or transported into the circulation to reach 
other organs, such as the liver and muscles. SCFAs exert direct and indirect regulatory effects 
on epithelial cells, antigen-presenting cells, and T cells via multiple mechanisms including 
metabolic regulation, histone deacetylase inhibition (HDAC inhibition), and G-protein–cou-
pled receptor (GPCR) activation.
SCFAs can be converted to Acetyl-CoA and integrated into the citric acid cycle (Krebs cycle). 
Acetyl-CoA is a central molecule that stores energy and is eventually oxidized to CO
2
 for 
energy production (the cellular energy [ATP/ADP] level increases). This boosts a homeostatic 
T-cell sensor mammalian target of rapamycin (mTOR) to be activated in T cells which skews 
T-cell differentiation into effector T cells such as Th1 and Th17 cells at the expense of FoxP3+ T 
cells. mTOR activation also promotes the generation of IL-10+ cells. Thus, the SCFA regulation 
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of cell metabolism and mTOR accounts for the increased generation of Th1 cells, Th17 cells, 
and IL-10+ cells.
The activation of SCFA-binding G-protein–coupled receptors (GPCRs) such as GPR41, GPR43, 
GPR109A, and Olfr78 initiates T-cell differentiation.
All major SCFAs such as C2, C3, C4, and C5 have HDAC inhibitor activity. Class I/II HDACs 
are major targets of SCFA inhibition in a concentration-dependent pattern. Treg generation 
was increased as a result of HDAC inhibition by SCFAs and histone H3 acetylation in key 
regulatory regions of the Foxp3 locus.
SCFAs can indirectly affect T cells through their effects on DCs. They suppress the develop-
ment of bone marrow progenitors into myeloid DCs and inhibit functional maturation of 
DCs in vitro. For example, C4 suppressed the maturation of bone marrow-derived DCs and 
production of IL-12 but increased the expression of IL-23p19. Valproic acid, a branched short-
chain fatty acid and potent HDAC inhibitor that suppressed the maturation of human DCs in 
vitro, inhibits the upregulation of T-cell–activating molecules such as MHC II, CD80, CD86, 
and IL-12.
These effects are combined to create the overall tolerogenic gut environment with a strong 
barrier function.
2.3.1.3. Microbiota and cytokine production
Microbiota produce stimulatory signals to gut macrophages to produce interleukin-1 (IL-1). 
IL-1 acts on type 3 innate lymphoid cells in the intestine, producing colony-stimulating fac-
tor 2 (CSF-2). CSF-2 induces myeloid cells (including dendritic cells and macrophages) to 
produce immune regulatory cytokines (retinoic acid and IL-10) which support the conver-
sion and expansion of regulatory T cells (Treg) critical for maintaining immune tolerance in 
the gut.
Microbiota have the capacity to produce a certain set of microbial products—gut microbiota–
derived butyrate and polysaccharide A PSA (e.g., Bacteroides fragilis) that mediates the con-
version of CD4+ T cells into Interleukin (IL)-10 producing Foxp3+ Treg cells offering immune 
protection. Such microbiome-derived molecule further promotes immunologic tolerance via 
TLR2 signaling pathway directly on Foxp3(+) Treg cells [47, 48].
The “segmented filamentous bacterium (SFB)” is another symbiotic gut commensal that 
is capable of inducing the appearance and activation of Th17 cells in the lamina propria, 
which secrete the pro-inflammatory cytokine (IL-17) and thereby enhance mucosal immune 
responses of the host [49].
2.3.1.4. Experimental evidences illustrated the impact of dysbiosis on the immune system and  
T-cell function
Multiple experimental evidences revealed that a germ-free environment is associated with 
a decline in neutrophil count and function [42–45]. Recognition of peptidoglycans from gut 
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microbiota by the cytosolic recognition receptor nucleotide oligomerization domain 1 (NOD1) 
is capable of enhancing the killing activity of marrow-derived neutrophils contributing to 
immune integrity. A germ-free environment was associated with impaired neutrophil phago-
cytic function, superoxide function, and nitric oxide generation, which could not be restored 
upon pathogen exposure. Germ-free rats lack the microbe-derived ATP capable of stimulating 
dendritic cells (CD70 and CX3CR1) involved in the subsequent differentiation of Th17 cells. 
Additionally, in germ-free rats, systemic, not gut macrophages, were reduced, and gut mac-
rophages lack macrophage-activation markers, such as MHC class II.
Early-life microbial exposures alter sex hormone levels and modify the progression to autoim-
munity in the nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D). Colonization 
by commensal microbes elevated serum testosterone and protected NOD males from T1D. 
Furthermore, transfer of gut microbiota from adult males to immature females altered the 
recipient’s microbiota, resulting in elevated testosterone and metabolomic changes, reduced 
islet inflammation and autoantibody production, and T1D protection [45].
3. The gut-microbiome checkpoints
Under normal conditions the human body has established a number of locally protective 
mechanisms and checkpoints to maintain immune integrity. These checkpoints include:
3.1. Mucosal buffer zone: “first-line defense”
Mucosal buffer zone represents an effective physicochemical barrier which is composed of 
the thick mucus layer, a number of antimicrobial proteins, and secretory IgA antibodies. The 
components of this barrier coalesce to minimize the contact and dilute any possible patho-
logical microbial trigger between the commensal microbes in the gut lumen and intestinal 
epithelial cells that line the gut wall [50, 51].
3.2. Intestinal epithelial cells: “second-line defense”
Microbiota that escape the initial “buffer zone” encounter a second defense strategy repre-
sented by the tight junctions formed between the intestinal epithelial cells featuring a physical 
barrier.
Epithelial cells produce a variety of antimicrobial/bactericidal proteins, such as defensins, cat-
helicidins, and C-type lectins and express Toll-like receptors (TLRs) in their cell membrane. 
Toll-like receptors (TLRs) present on the surface of cells of innate immunity recognize patho-
gen-associated molecular patterns (PAMPs) with activation of the signaling adaptor mole-
cule MyD88 (myeloid differentiation primary-response protein 88) provoking a downstream 
inflammatory responses. Lipopolysaccharides (LPS) are important components of the outer 
membrane of all Gram-negative bacteria. TLR4 is a natural ligand for LPS and upon binding 
to LPS leads to activation of cell and secretion of inflammatory cytokines. Cytokines in turn 
activate cells of the adaptive immune system that generates antigen-specific response [52].
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3.3. The Innate and Adaptive Immune responses of the Lamina Propria “Third-Line 
Defense”
The composition and function of the gut microbiota play a critical role in regulating the Th17/
Treg cell balance in the lamina propria. The innate cells in lamina propria constitute an important 
local line of immune defense that constantly surveys the gut lumen tracing undesirable antigens. 
The first is the intestinal macrophage system that phagocytoses microorganisms bypassing the 
first- and second-line barriers. The second is the lamina propria dendritic cells (DCs, antigen-
presenting cells) that present foreign peptides complexed with MHC class II molecules for prim-
ing of antigen-specific B- or T-cell receptors to initiate an adaptive immune response.
T helper cells feature another key player when primed via a complex network of receptors, 
cytokines, and transcription factors enabling their differentiation into several pro-inflamma-
tory or anti-inflammatory subsets. The type 1 T helper (Th1) response develops in response 
to intracellular pathogens, while type 2 T helper (Th2) and type 17 T helper (Th17) cells are 
predominantly stimulated after identification of extracellular organisms [53, 54].
4. Dysbiosis and autoimmune inflammatory arthritis
Multiple animal models of human autoimmune diseases (AD) suggest the direct involvement 
of commensal microbiota in disease development. A change to a single bacterial species and/
or the entire community leads to an imbalance between the pathobiome and the symbiome 
immune responses with breakdown of self-immune tolerance provoking a number of ADs 
[47]. Mono-colonization with Lactobacillus bifidus in IL-1 receptor antagonist knockout mice 
resulted in rapid onset of arthritis which was dependent on Toll-like receptor activation by 
L. bifidus. The arthritis onset was preventable by promoting a germ-free environment [52]. 
Mono-colonization of germ-free mouse with single gut-microbiome “segmented filamentous 
bacterium (SFB)” is sufficient to induce fully functional TH17 cells that produce pro-inflam-
matory cytokines IL-17 and drive the onset of arthritis. The SFB upregulates the production of 
acute-phase isoforms of serum amyloid A (SAA) in the ileum, which can act on dendritic cells 
(DCs) from the small intestinal lamina propria to induce Th17 differentiation [49, 55]. Also, 
colonization of the mice gut with Prevotella copri (P. copri) can enhance experimental dex-
tran sulfate sodium-induced colitis which is capable of initiating a pro-inflammatory drive in 
human arthritis. The P. copri genome encodes phosphoadenosine phosphosulfate reductase, 
an oxidoreductase that participates in the production of thioredoxin. Thioredoxin (TRX) is a 
cellular reducing catalyst induced by oxidative stress and is involved in the redox regulation 
of transcription factors such as NF-kappa B. TRX has been widely implicated in the patho-
genesis of RA with significantly increased concentrations observed in both RA serum and 
synovial fluid [56–58].
Finally, commensal bacteria can produce and secrete large amounts of adenosine 51-triphosphate 
(ATP) that can activate a unique subset of lamina propria cells, CD70highCD11clow cells. The 
CD70highCD11clow subset cells could express Th17-inducing molecules, such as IL-6, IL-23p19, 
and transforming-growth-factor-_-activating integrin AV, and induce Th17 differentiation [59].
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The metabolome theory: The analysis of bacterial metabolites and their association with specific 
taxa unveiled significant scientific data on potential mechanistic link in RA. The abundance 
of the Collinsella genus correlated strongly with high levels of three metabolites (beta-alanine, 
alpha-aminoadipic acid, and asparagine) in RA. The immune-stimulatory role of the Collinsella 
in RA was confirmed using a human epithelial cell line and a humanized mouse model of colla-
gen-induced arthritis (CIA). Collinsella increased gut permeability by reducing the expression of 
tight junction protein in the human intestinal epithelial cell line CACO-2, induced production 
of the pro-inflammatory cytokine interleukin IL-17A. In humanized CIA, Collinsella enhanced 
disease severity. All together, these data suggest that it seems to have an essential role in alter-
ing gut permeability and disease severity as confirmed in experimental arthritis [60].
5. Altered Gut Microbiota and Inflammation in Rheumatoid Arthritis.
The Th17 pathway is one of the main inflammatory pathways. Th17 cells and its signature 
cytokine IL-17 have been involved in mediating pannus growth, osteoclastogenesis, and 
 synovial neo-angiogenesis. Circulating Th17 cells as well as the IL-17 are significantly elevated 
in patients with RA. IL-17 induces RANKL expression in human synovial fibroblasts, leading 
to the loss of the RANKL/OPG balance with subsequent enhancement of osteoclastogenesis 
and bone erosion. IL-17 also increases the production of vascular endothelial growth factor 
(VEGF) in rheumatoid fibroblast-like synoviocytes (FLS), contributing to the angiogenesis in 
rheumatoid synovium. Finally, IL-17 stimulates the expression of various pro-inflammatory 
cytokines (e.g., IL-1β, TNF-α, and IL-6) and matrix-degrading enzymes (e.g., matrix metal-
loproteinase (MMP)-1, matrix metalloproteinase-2, matrix metalloproteinase-9, and matrix 
metalloproteinase-13) in whole synovial tissue, synovial fibroblasts, and cartilage, thus pro-
moting inflammation, extracellular matrix breakdown, and cartilage destruction during RA 
development [61–65].
The gut mucosa represents a strategic landscape promoting a variety of interactions between 
the environment and the human host. They possess the potential to trigger autoimmunity in 
diverse ways. When genetic and/or environmental factors alter the balance in the microbiota 
composition, dysbiosis ensues. The metagenomics shotgun sequencing technique has revealed 
significant alterations in the microbiota profile in patients with RA. Evidences illustrated that 
changes in the symbiotic relationship between intestinal microflora and opportunistic bacteria 
as well as bacterial translocation from the gut to nasal mucosa or urinary tract may addition-
ally enhance the risk of developing RA as well as disease-related comorbid conditions. Partial 
depletion of natural gut flora by antibiotic in experimental animals aggravates CIA [53].
Potentially harmful microorganisms/pathobiomes (such as SFB or Lactobacillus) dominate and 
create a local pro-inflammatory profile with local expansion of autoreactive Th1 and Th17-cell 
compartments, via secretion of stimulatory molecules as ATP adenosine-5′-triphosphate, SAA 
serum amyloid A, or CCL5 CC-chemokine ligand 5 signaling. The autoreactive T cells migrate 
to peripheral immune compartments and activate B cells to differentiate into autoantibody-
producing plasma cells. These cells and antibodies then migrate to synovial tissue where 
the inflammatory cascade is amplified through the activation of effector components, includ-
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ing macrophages, fibroblasts, osteoclasts, cytokines, and proteinases provoking arthritis and 
pannus formation. Dysbiosis in RA is associated with clinical indices of immune-mediated 
inflammation, such as the titers of immunoglobulin, autoantibodies, anti-cyclic citrullinated 
peptide (anti-CCP), and rheumatoid factor (RF) [17, 52, 55, 66].
5.1. Microbial colonies overpresented in RA
5.1.1. The Lactobacillus species
Lactobacillus fecal microbiome communities were found to be significantly increased in 
patients with early RA with those from healthy individuals [25] (Table 1). The abundance 
of Lactobacillus salivarius was associated with an increase in disease severity associating the 
increase in bacterial load.
5.1.2. The Prevotella copri species
A strong positive correlation was illustrated between the Prevotella copri (P. copri) and new-
onset untreated RA (NORA). Prevotella was found to be overrepresented in NORA patients, 
and the relative abundance of P. copri in RA patients negatively correlates with the presence of 
HLA-DRB1-shared epitope. The relation between this specific microbiome and RA was further 
confirmed by the observation that the expansion of P. copri in RA patients could be suppressed 
to a similar state that was observed in healthy subjects after treatment with DMARDs that 
control of RA disease activity.
Study Patients vs. controls 
(number)
Sample Technique Microbiota profile
Increased (++), decreased (--)
Vaahtovuo et al. [67] Early RA (n= 51) vs. 
fibromyalgia (n= 50)
Stool 16S rRNA 
hybridization and 
DNA staining
Bifidobacteria --, Bacteroides --, 
Porphyromonas --, Prevotella --, 
Bacteroides fragilis --, Clostridium 
coccoides --
Gul’neva et al. [68] Treatment-naïve RA 
(n= 94) vs. healthy 
(n= 97)
Stool, dental, 
saliva
Metagenomic 
shotgun 
sequencing
Lactobacillus salivarius ++, 
Gordonibacter pamelaeae ++, 
Clostridium asparagiforme ++, 
Haemophilus spp. --
Liu et al. [69] Early RA (n= 15) vs. 
healthy (n= 15)
Stool Quantitative real-
time PCR
Lactobacillus ++
Scher et al. [57] New-onset RA (n= 
44) vs. healthy (n= 28)
Stool 16S rRNA 
gene and WGS 
sequencing
Prevotella copri ++, 
Bacteroidetes --
Zhang et al. [70] RA (n= 30) vs. 
healthy (n= 30)
Stool 16S rRNA 
gene and WGS 
sequencing
Enterococci ++, Clostridia ++, 
Colibacteria ++, Lactobacteria --
Table 1. Microbiota profile in RA [57, 67–70].
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5.1.3. Other forms of gut microbiota
RA patients showed a dysbiotic gut microbiota characterized by a decrease in Faecalibacterium 
and an increase in Collinsella and Eggerthella. Large microbiota clusters including Gordonibacter 
pamelaeae, Clostridium asparagiforme, Eggerthella lenta, and Lachnospiraceae bacterium as well 
as small clusters of Bifidobacterium dentium and Ruminococcus lactaris were enriched in the gut 
of RA patients.
On the other hand, RA patients have significantly less bifidobacteria and microbiome of the 
Bacteroides-Porphyromonas-Prevotella group, Bacteroides fragilis subgroup, and Eubacterium 
rectale-Clostridium coccoides group and Haemophilus spp. in comparison to patients with non-
inflammatory rheumatic diseases.
5.1.4. Protective microbiota species: Prevotella histicola “P. histicola”
Oral feeding of P. histicola in mouse models of RA led to decreased symptom frequency and 
severity and fewer signs of inflammation in diseased vs. controls. P. histicola administration is 
associated with an upregulation of the anti-inflammatory cytokine IL-10 and Treg cells in the 
lamina propria and spleen of mice with CIA with subsequent amelioration of immune inflam-
matory responses. P. histicola preserves gut epithelium integrity by lowering gut permea-
bility and increased expression of tight junction proteins (zonulin and occludin) in treated 
mice compared to control. Treatment with P. histicola had fewer side effects (such as weight 
gain, villous atrophy, and increased gut permeability) that are linked with nonsteroidal anti-
inflammatory drugs and other traditional medications used for treating RA. This microbiome 
is currently considered as potential future novel therapy in RA [71].
6. Future perspectives
Multiple lines of evidence support the potential pathogenic role of gut dysbiosis in RA which 
makes gut microbiota a possibly promising new territory for drug targeting [72]. Restoring 
balance of gut microbiota might contribute to the improvement of disease symptoms in RA. 
Experimental models demonstrated the ability of certain microbial colonies to drive inflam-
mation such as P. copri and SFB.
Thus, it is plausible to hypothesize that targeting the postulated pathobiomes might contrib-
ute to clinical improvement in RA. Despite the successful use of antimicrobials in RA, they 
lack microbial specificity in most studies.
“Mapping of the individual’s microbiota profile and tracking their metabolic signatures 
might serve in the future design of a predictive profile of the potential to develop inflam-
matory arthritis, anticipate disease course, severity and specify more therapeutic strategies.”
“Restoring balance in dysbiosis represents an advent toward novel treat to target therapeutic 
strategies in RA, a promising step toward an effective personalized medical approach.”
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